Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial

Lee, Thomas K.M.; Clandinin, Michael T.; Hébert, Marc; MacDonald, Ian M.

doi:10.3129/i10-028

Cited by 11 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have a very small sample size, especially the one published by Lee et al, with eight participants, and therefore their findings present a limited global application. 18 In the opposite end we find the RCT with factorial design conducted by Berson et al 12 with 601 randomised participants. Other included studies might be at risk of bias as they present a high rate of dropouts (420%), 9,11 or as in the study conducted by Hoffman et al in 2014 do not inform clearly about patients and researchers blinding procedure.…”

Section: Resultsmentioning

confidence: 99%

“…Other included studies might be at risk of bias as they present a high rate of dropouts (420%), 9,11 or as in the study conducted by Hoffman et al in 2014 do not inform clearly about patients and researchers blinding procedure. 18 The study by Bahrami et al has an important limitation regarding the method used for data recording, as they were documented by participants on their own using their personal computers. 11 All studies performed intention-to-treat analysis with the exception of Rotenstreich et al 19 Figure 1 Flowchart for the selection of studies.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…All are randomised controlled trials, with a parallel design, 9,10,13,14,16 a crossover design, 11,19,18 or a factorial design. 12 Except Lee et al which studied Best disease, 18 all included studies are on RP. [9][10][11][12][13][14][15][16][17][19][20][21] They assessed supplements based on vitamin A and vitamin E, 12 docosahexaenoic acid (DHA), 9,10,14,16,18 and the carotenoids lutein, 11,13 and β-carotene.…”

Section: Resultsmentioning

confidence: 99%

“…Finally, 8 studies informed in 13 articles were included in the present review. [9][10][11][12][13][14][15][16][17][18][19][20][21] Characteristics of studies…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review

Brito-García

Pino-Sedeño

Trujillo-Martín

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Finally, 8 studies informed in 13 articles were included in the present review. [9][10][11][12][13][14][15][16][17][18][19][20][21] Characteristics of studies…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review

Brito-García

Pino-Sedeño

Trujillo-Martín

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

Four-Year Placebo-Controlled Trial of Docosahexaenoic Acid in X-Linked Retinitis Pigmentosa (DHAX Trial)

et al. 2014

View full text Add to dashboard Cite

IMPORTANCE X-linked retinitis pigmentosa is a severe inherited retinal degenerative disease with a frequency of 1 in 100 000 persons. Because no cure is available for this orphan disease and treatment options are limited, slowing of disease progression would be a meaningful outcome.OBJECTIVE To determine whether high-dose docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty acid, slows progression of X-linked retinitis pigmentosa measured by cone electroretinography (ERG). DESIGN, SETTING, AND PARTICIPANTSA 4-year, single-site, randomized, placebo-controlled, double-masked phase 2 clinical trial at a research center specializing in medical retina. Seventy-eight male patients diagnosed as having X-linked retinitis pigmentosa were randomized to DHA or placebo. Data were omitted for 2 patients with non-X-linked retinitis pigmentosa and 16 patients who were unable to follow protocol during the first year. The remaining participants were tested annually and composed a modified intent-to-treat cohort (DHA group, n = 33; placebo group, n = 27).INTERVENTIONS All participants received a multivitamin and were randomly assigned to oral DHA (30 mg/kg/d) or placebo. MAIN OUTCOMES AND MEASURESThe primary outcome was the rate of loss of cone ERG function. Secondary outcomes were rod and maximal ERG amplitudes and cone ERG implicit times. Capsule counts and red blood cell DHA levels were assessed to monitor adherence.RESULTS Average (6-month to 4-year) red blood cell DHA levels were 4-fold higher in the DHA group than in the placebo group (P < .001). There was no difference between the DHA and placebo groups in the rate of cone ERG functional loss (0.028 vs 0.022 log μV/y, respectively; P = .30). No group differences were evident for change in rod ERG (P = .27), maximal ERG (P = .65), or cone implicit time (no change over 4 years). The rate of cone loss (ie, event rate) was markedly reduced compared with rates in previous studies. No severe treatment-emergent adverse events were found.CONCLUSIONS AND RELEVANCE Long-term DHA supplementation was not effective in slowing the loss of cone or rod ERG function associated with X-linked retinitis pigmentosa. Participant dropout and lower-than-expected disease event rate limited power to detect statistical significance. A larger sample size, longer trial, and attainment of a target blood DHA level (13%) would be desirable. While DHA supplementation at 30 mg/kg/d does not present serious adverse effects, routine monitoring of gastrointestinal tolerance is prudent. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00100230

show abstract

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Abdelhamid

Brown

Brainard

et al. 2018

Cochrane Database of Systematic Reviews

391

298

View full text Add to dashboard Cite

Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical trial

Cited by 11 publications

References 27 publications

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review

Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review

Four-Year Placebo-Controlled Trial of Docosahexaenoic Acid in X-Linked Retinitis Pigmentosa (DHAX Trial)

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Contact Info

Product

Resources

About